



EUROPEAN
HEMATOLOGY
ASSOCIATION

 **haematologica**

Journal of the European Hematology Association
Owned & published by the Ferrata Storti Foundation

AUTHOR CONTRIBUTION FORM

Title	<i>Radotinib in the treatment of chronic phase chronic myeloid leukemia patients</i>
First author	<i>Ahmet Emre Eskazan</i>

According to the International Committee of Medical Journal Editors (ICMJE)

(http://www.icmje.org/ethical_1author.html):

“Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2 and 3. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship”.

The responsible author of this manuscript confirms that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

Responsible author (<i>author responsible for the integrity of the work as a whole</i>)
Name: Ahmet Emre Eskazan
Institute: Istanbul University Cerrahpasa Faculty of Medicine
e-mail: emreeskazan@hotmail.com

Author contributions

Please describe the contributions of each author, indicating who was responsible for each part of the study and the preparation of the manuscript (collection of data, experiments, data analysis, generation of figures, interpretation of data, preparation of the text, etc.) :

Ahmet Emre Eskazan and Teoman Soysal both wrote the manuscript.